Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

USA - NYSEARCA:ATNM - US00507W2061 - Common Stock

1.46 USD
0 (0%)
Last: 10/17/2025, 8:04:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ATNM. ATNM was compared to 536 industry peers in the Biotechnology industry. ATNM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATNM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATNM had negative earnings in the past year.
ATNM had a negative operating cash flow in the past year.
In the past 5 years ATNM always reported negative net income.
In the past 5 years ATNM reported 4 times negative operating cash flow.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

ATNM has a Return On Assets (-65.12%) which is comparable to the rest of the industry.
ATNM has a worse Return On Equity (-215.83%) than 68.41% of its industry peers.
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ATNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATNM has more shares outstanding
ATNM has more shares outstanding than it did 5 years ago.
ATNM has a better debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATNM has an Altman-Z score of -9.55. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
ATNM has a worse Altman-Z score (-9.55) than 71.96% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
ATNM has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ATNM outperforms 50.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.55
ROIC/WACCN/A
WACC9.35%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
ATNM has a Current ratio of 7.34. This is in the better half of the industry: ATNM outperforms 70.47% of its industry peers.
ATNM has a Quick Ratio of 7.34. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 71.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.82% over the past year.
The Revenue for ATNM has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)13.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ATNM will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.76% on average per year.
The Revenue is expected to grow by 266.09% on average over the next years. This is a very strong growth
EPS Next Y-7.22%
EPS Next 2Y9.03%
EPS Next 3Y4.85%
EPS Next 5Y12.76%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y266.09%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.03%
EPS Next 3Y4.85%

More info and screens

0

5. Dividend

5.1 Amount

ATNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (10/17/2025, 8:04:01 PM)

1.46

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-12 2025-11-12
Inst Owners20.8%
Inst Owner Change0%
Ins Owners1.79%
Ins Owner Change-1.12%
Market Cap45.55M
Analysts81.82
Price Target5.1 (249.32%)
Short Float %2.86%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -9.55
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)24.36%
Cap/Depr(5y)31.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
EPS Next Y-7.22%
EPS Next 2Y9.03%
EPS Next 3Y4.85%
EPS Next 5Y12.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y266.09%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.56%
EBIT Next 3Y-2.6%
EBIT Next 5Y-5.07%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A